Association of aspirin use with major bleeding in patients with and without diabetes.

CONTEXT The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without diabetes. This benefit could easily be offset by the risk of hemorrhage. OBJECTIVE To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes taking aspirin. DESIGN, SETTING, AND PARTICIPANTS A population-based cohort study, using administrative data from 4.1 million citizens in 12 local health authorities in Puglia, Italy. Individuals with new prescriptions for low-dose aspirin (≤300 mg) were identified during the index period from January 1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during this period. MAIN OUTCOME MEASURES Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation of antiplatelet therapy. RESULTS There were 186,425 individuals being treated with low-dose aspirin and 186,425 matched controls without aspirin use. During a median follow-up of 5.7 years, the overall incidence rate of hemorrhagic events was 5.58 (95% CI, 5.39-5.77) per 1000 person-years for aspirin users and 3.60 (95% CI, 3.48-3.72) per 1000 person-years for those without aspirin use (incidence rate ratio [IRR], 1.55; 95% CI, 1.48-1.63). The use of aspirin was associated with a greater risk of major bleeding in most of the subgroups investigated but not in individuals with diabetes (IRR, 1.09; 95% CI, 0.97-1.22). Irrespective of aspirin use, diabetes was independently associated with an increased risk of major bleeding episodes (IRR, 1.36; 95% CI, 1.28-1.44). CONCLUSIONS In a population-based cohort, aspirin use was significantly associated with an increased risk of major gastrointestinal or cerebral bleeding episodes. Patients with diabetes had a high rate of bleeding that was not independently associated with aspirin use.

[1]  A Nicolosi,et al.  The burden of hospitalization related to diabetes mellitus: a population-based study. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  G. Tognoni,et al.  Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. , 2012, European heart journal.

[3]  Eric E. Smith,et al.  Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis , 2011, Circulation.

[4]  L. Køber,et al.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study , 2011, BMJ : British Medical Journal.

[5]  A. Fendrick,et al.  Cost-utility of aspirin and proton pump inhibitors for primary prevention. , 2011, Archives of internal medicine.

[6]  K. Huber,et al.  Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[7]  Mary Cushman,et al.  Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation , 2010, Circulation.

[8]  G. Berardis.  Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.

[9]  G. Tognoni,et al.  Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk , 2009, European Journal of Clinical Pharmacology.

[10]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[11]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[12]  F. Crea,et al.  COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. , 2009, European heart journal.

[13]  J. Hallas,et al.  Do statins protect against upper gastrointestinal bleeding? , 2009, British journal of clinical pharmacology.

[14]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[15]  M. Rawlins.  De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.

[16]  D. Ferrante,et al.  Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction , 2008, European Journal of Clinical Pharmacology.

[17]  E. Rahme,et al.  Hospitalization for gastrointestinal adverse events attributable to the use of low‐dose aspirin among patients 50 years or older also using non‐steroidal anti‐inflammatory drugs: a retrospective cohort study , 2007, Alimentary pharmacology & therapeutics.

[18]  G. Tognoni,et al.  The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure , 2007, European journal of heart failure.

[19]  P. Russo,et al.  Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study. , 2007, Clinical therapeutics.

[20]  Peter C Austin,et al.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study , 2007, Statistics in medicine.

[21]  Á. Lanas,et al.  Low-dose aspirin and upper gastrointestinal damage:epidemiology, prevention and treatment , 2007, Current medical research and opinion.

[22]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[23]  L. Laine,et al.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.

[24]  F. Raoux.  Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. , 2006 .

[25]  Craig S. Anderson,et al.  Risk Factors for Subarachnoid Hemorrhage: An Updated Systematic Review of Epidemiological Studies , 2005, Stroke.

[26]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[27]  Elaine L. Zanutto,et al.  Estimating causal effects of public health education campaigns using propensity score methodology , 2005 .

[28]  曲东锋.  Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .

[29]  Á. Lanas,et al.  Risk of upper gastrointestinal bleeding in patients taking low‐dose aspirin for the prevention of cardiovascular diseases , 2002, Alimentary pharmacology & therapeutics.

[30]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.

[31]  Á. Lanas,et al.  Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. , 2000, The New England journal of medicine.

[32]  S. Hernández-Díaz,et al.  Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. , 2000, Archives of internal medicine.

[33]  M. Rawlins,et al.  Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs , 2000, Gut.

[34]  P. Whelton,et al.  Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. , 1998, JAMA.

[35]  Aspirin for the prevention of cardiovascular disease: recommendation statement. , 2011, American family physician.

[36]  Sanjay Kaul,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Journal of the American College of Cardiology.

[37]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[38]  N. Crepaz,et al.  Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States , 2011, Cancer Causes & Control.

[39]  T. Inagawa.  Risk factors for aneurysmal subarachnoid hemorrhage in patients in Izumo City, Japan. , 2005, Journal of neurosurgery.

[40]  E. Winkler.  Comparative Analysis of Record Linkage Decision Rules , 2002 .

[41]  Lori S. Parsons.  Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .